Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

Blood. 2006 Sep 1;108(5):1782-3. doi: 10.1182/blood-2006-03-011668.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Dasatinib
  • Fusion Proteins, bcr-abl / genetics*
  • Genes, abl*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Mutation*
  • Piperazines / administration & dosage
  • Pyrimidines / administration & dosage
  • Thiazoles / administration & dosage

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib